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Background/Aims: Clevudine is a pyrimidine analogue with potent activity against hepatitis B virus (HBV) replication in vitro. In a 
previous pivotal phase III clinical study, 24 weeks treatment with clevudine 30 mg has been shown to profoundly suppress HBV 
replication and normalize serum alanine aminotransferase level. Methods: In this study, we compare the efficacy and safety of 
clevudine (30 mg daily) versus lamivudine (100 mg daily) for 48 weeks in treatment-naive chronic hepatitis B e antigen (HBeAg) 
positive patients. Results: Ninety-two chronic HBeAg positive patients were randomized to receive clevudine 30 mg daily or 
lamivudine 100 mg daily in a 1:1 ratio. The clevudine group demonstrated greater viral suppression at week 48 when compared 
with the lamivudine group (median reduction: 4.27 vs. 3.17 log10 copies/ml at week 48, p<0.0001). At week 48, serum HBV DNA 
level was below 300 copies/mL in 73% and 40% in the clevudine and lamivudine groups, respectively (p=0.001). HBeAg 
seroconversion occurred in 18% of patients in the clevudine group versus 12% in the lamivudine group at week 48. 
Lamivudine-resistant mutations were detected in 11 (24%) patients in the lamivudine group, who showed viral rebound during 
lamivudine therapy but no resistance was found in the clevudine group during 48-week treatment period. Conclusions: A 48-week 
dosing with clevudine 30 mg daily was superior to lamivudine 100 mg daily in suppressing HBV replication, with no emergence of 
viral breakthrough in patients with HBeAg positive chronic hepatits B. (Korean J Hepatol 2010;16:315-320)
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INTRODUCTION
Worldwide and especially in Asia-Pacific region, chronic 
hepatitis B (CHB) virus infection is the major cause of 
liver-related morbidity and mortality.
1-3 Indeed, it is estimated 
that one-quarter of chronic HBV patients will die from 
hepatocellular carcinoma and end-staged liver cirrhosis. The 
virus is transmitted via contact with blood, semen, or saliva of 
those with acute, chronic or active infection and perinatal 
transmission from an infected mother to child is the major route 
of infection in Southeast Asia.
4 It is estimated that there are 350 
million chronic HBV patients, worldwide.
5 The primary aim of 
treatment is to achieve sustained immune control on viral 
replication, which is associated with long-term clinical benefits. 
This is defined as hepatitis B ‘e’ antigen (HBeAg) seroconversion 
in HBeAg-positive patients and sustained HBV DNA suppression 
to less than 10,000 copies/mL in HBeAg-negative patients.
6 
Though lamivudine is effective in reducing HBV viral replication, 
prolonged therapy leads to the development of drug-resistant 
mutants, which will adversely affect the natural history of 
chronic HBV infection.
7 Previously clevudine at the dose of 30 
mg daily has been shown to produce potent antiviral activity with 
a prolonged viral suppression after 24 weeks of treatment for 
chronic HBeAg-positive patients.
8 The median log10 HBV DNA 
change from baseline was -5.10 log10 copies/mL and 68% of 
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aminotransferase (ALT) level. Sixty-five percent (65%) of 
patients had HBV DNA levels below the lower limit of detection 
(LOD) by Digene HC II assay (4,700 copies/mL), and 59% had 
negative HBV DNA levels (<300 copies/mL) by Amplicor PCR 
at the end of 24 weeks of treatment. At 6 months post-treatment, 
viral suppression was sustained with a median suppression of 
-2.02 log10 copies/mL. Furthermore, near to one-fifth of patients 
had serum HBV DNA below LOD by Digene HC II assay (4,700 
copies/mL) and 61% had normal ALT at 6 months post- 
treatment. The prolonged anti-viral effect after withdrawal from 
clevudine is unknown.
9 Therefore, based on the hypothesis that 
dosing with clevudine for at least 1 year may provide more 
prolonged and profound suppression of HBV DNA, we designed 
the current double-blinded study to evaluate the safety and 
antiviral activity for a 48-week treatment of clevudine 30 mg 
daily compared with lamivudine 100 mg daily in patients with 
HBeAg-positive chronic hepatitis B. 
PATIENTS AND METHODS
1. Study design
This is a double-blinded, randomized, clinical study. It was 
conducted at two clinical centers in Hong Kong (Queen Mary 
Hospital and Alice Ho Miu Ling Nethersole Hospital, Hong 
Kong). Patients were randomized, based on a predetermined 
computer generated list, to receive either clevudine 30 mg or 
lamivudine 100 mg (1:1) once daily for 48 weeks. 
The study was conducted in accordance with the principles of 
the Declaration of Helsinki and in compliance with Good 
Clinical Practice guidelines. Written informed consent was 
obtained from all study participants before being examined for 
eligibility criteria. The study protocol and the informed consent 
form were approved by the ethics committee at each study site.
Patients were monitored at baseline, week 4, 8, 12, 16, 20, 24, 
32, 40 and week 48 during the dosing period. Patients underwent 
clinical assessments of tolerability (open-ended interview), 
physical exam and blood samples were tested according to the 
protocol.
A sub-study on hepatitis B viral dynamic was done. The 
sub-study involved the first 30 enrolled patients. The purpose of 
the sub-study was to define the nature of the antiviral effect of 
clevudine compared to lamivudine. A separate consent was 
obtained from the study patients participated in this sub-study. If 
the patient agreed to participate in this sub-study, they were 
asked to visit the clinic on day 4, 7, 10, 14, week 3 before the visit 
at week 4 of the main study.
2. Study population
Eligible patients were adults, 18-60 years of age, with chronic 
HBeAg-positive hepatitis. They all have hepatitis B surface and 
e antigen positive for at least 6 months, with a serum HBV DNA 
levels more than 3×10
6 copies/mL and serum ALT levels between 
1.0 and 10 times the upper limit of normal (ULN). Exclusion 
criteria included co-infection with hepatitis C, or the human 
immunodeficiency virus; evidence of cirrhosis or hepatocellular 
carcinoma; previous exposure to any nucleoside analog that is 
active against HBV; use of interferon alpha within 6 months 
before enrollment. Patients who were taking any traditional 
Chinese medication, or had been taking any traditional Chinese 
medication within the last 2 weeks prior to screening were 
excluded. Breastfeeding or pregnant women or women of 
childbearing age unwilling to use barrier contraceptive methods 
were also excluded. 
The sample size was calculated to detect 30% of statistically 
significant differences in the proportion of patients with serum 
HBV DNA below 300 copies/mL at week 48 between the 
clevudine treatment group and the lamivudine group, assuming 
that lamivudine and clevudine responses were 36% and 67%, 
respectively. The sample size was estimated using the Z-test with 
an alpha level of 0.05 and 80% power for comparing lamivudine 
group with clevudine treatment group. The ratio of patient 
numbers in each group (lamivudine 100 mg daily versus 
clevudine 30 mg daily) was 1:1. According to this assumption, 
40 patients per group was required. Taking a small drop-out rate 
of around 10 percent, a total of 92 patients were enrolled, i.e., 46 
patients per group.
3. Efficacy endpoints
The primary efficacy end point was the proportion of patients 
with negative HBV DNA (<300 copies/ml) by Amplicor PCR at 
week 48. Serum HBV DNA levels were measured at a central 
laboratory using the COBAS Amplicor PCR assay (Roche 
Molecular Systems, Branchburg, NJ, USA) with a LOD of 
300 copies/mL. 
Secondary end points included the reduction in serum HBV 
DNA, as defined as median log10 decrease from baseline at week 
48, HBeAg loss, HBeAg seroconversion (HBeAg loss and 
appearance of anti-HBe), and serum ALT normalization. A viral George KK Lau, et al. 48-week treatment with clevudine versus lamivudine  317
Table 1. Patient characteristics at baseline
Clevudine
(n=46)
Lamivudine
(n=46)
P-value
Mean age (yr) 35.4±9.6 37.4±12.3 0.373
*
Gender  n (%)
  Male
  Female
29 (63)
17 (37)
26 (57)
20 (43)
0.524
†
Median HBV DNA
(log10 copies/mL) (range)
7.3 
(5.4-8.7)
7.3 
(5.0-8.7)
0.529
‡
Median ALT (U/L) (range) 72.5 
(21-367)
67.5 
(27-310)
0.369
‡
HBV, hepatitis B virus; ALT, alanine aminotransferase.
* Two sample t-test, 
† Chi-square test, 
‡ Wilcoxon rank-sum test.
 
        
 
        
Lamivudine  Clevudine
Baseline 
(Day 1) 
Week 4 
Eligible N=92 
N=46
N=45
N=45
N=45
N=17 
Sub-study  
(Day 4 to Week 3) 
N=45
N=45
N=45
N=45
N=45
N=43
Week 8 
Week 12 
Week 16 
Week 20 
Week 24 
Week 32 
Week 40 
Week 48 
N=46
N=46
N=45
N=45
N=13  
N=45
N=45
N=45
N=45
N=45
N=45
Figure 1. Flow chart of the present study.
breakthrough is defined as increase in serum HBV DNA by 1 log 
(10 fold) above nadir in patients with viral load initially 
suppressed by at least 2 logs from baseline.
The viral dynamic over the first 12 weeks was summarized by 
treatment groups for the sub-study on 30 subjects. Serial serum 
HBV DNA samples were analyzed by a viral load function 
previously applied to the clearance kinetics of HBV from serum 
during a lamivudine and famciclovir viral dynamics study.
10 The 
efficacy (ε) of inhibition of viral production, the free virus 
clearance rate constant (μ), and the infected cell loss rate constant 
(a) were determined by fitting the viral load function to the data 
using non-linear regression. 
4. Safety analysis
The safety analysis included data from all 92 eligible patients 
who received at least one dose of study medication after 
randomization. Safety evaluations included analysis of adverse 
events, serious adverse events, and deaths. Exacerbation of 
hepatitis B was defined as ALT and/or AST elevations (a) 
>20×ULN or (b) >10×ULN and a 10-fold change from the lowest 
on-study value. Exacerbation of hepatitis B was considered as a 
serious adverse event. 
5. Analysis of genotypic resistance
The analysis of the HBV DNA polymerase domain (amino 
acids 119-247) by dideoxy sequencing was performed at baseline 
and at the end of 48 weeks dosing period for all of the patients 
with positive HBV DNA by Amplicor PCR assay. For the 
detection of lamivudine-related YMDD mutations at rt180 and 
rt204, restriction fragment length polymorphism (RFLP) assay 
was performed additionally at baseline and at the end of 48 
weeks dosing period as described.
11 A genotypic resistance is 
defined as increase in serum HBV DNA by 1 log (10 fold) above 
nadir in patients with viral load initially suppressed by at least 2 
logs from baseline and genotypic mutation.
6. Statistical analysis
The results were analyzed on the basis of intention-to-treat 
and all 92 eligible patients who received at least one dose of 
study medication after randomization were included in the safety 
analysis. Patients discontinuing the study after receiving the first 
study drug dose were included in the efficacy analysis until the 
time of their discontinuation. 
The Statistical Analysis System (SAS) Release 9.2 was used 
for the statistical analysis. Statistical significance was performed 
with an alpha level of 0.05. A two-sided Chi-Square test was used 
to compare the difference of the proportion of patients with 
negative HBV DNA at week 48 between the two groups, ALT 
normalization, serology response and incidence of adverse 
events (AEs). Two-sample Wilcoxon rank sums test were used 
for viral dynamic analysis.
RESULTS
1. Study population
A total of 92 eligible patients were enrolled at two sites and 
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Table 2. Summary of viral and biochemical responses in the clevudine and lamivudine groups
Clevudine (n=46) Lamivudine (n=46) P-value
Serum HBV DNA below 300 copies/mL by Amplicor PCR assay (n/N, %)
  Week 12 5/45 (11%) 1/45 (2%)
  Week 24 21/45 (47%) 10/45 (22%)
  Week 32 29/45 (64%) 15/45 (33%)
  Week 48 33/45 (73%) 17/43 (40%) 0.001
*
Normal ALT (n/N, %)
  Week 12 27/45 (60%) 23/45 (51%)
  Week 24 37/45 (82%) 35/45 (78%)
  Week 32 38/45 (84%) 38/45 (84%)
  Week 48 35/45 (78%) 35/43 (81%) 0.591
†
*McNemar’s test, 
†Chi-Square test.
Table 3. Estimates of viral dynamics parameters 
Parameter Group N N Miss Mean SD Med. Min. Max. Q1 Q3 P-value
*
ε
Lamivudine 17 0 0.930 0.085 0.962 0.699 0.997 0.906 0.982
0.060
Clevudine 11 2 0.975 0.035 0.989 0.884 1.000 0.961 0.997
μ
Lamivudine 17 0 0.669 0.345 0.740 0.097 1.188 0.338 0.968
0.371
Clevudine 11 2 0.936 0.685 0.735 0.307 2.785 0.495 1.125
a
Lamivudine 17 0 0.050 0.025 0.046 0.015 0.103 0.027 0.062
0.672
Clevudine 11 2 0.051 0.016 0.054 0.011 0.069 0.045 0.063
R002 was excluded because of numerical issue (Estimates were biased) and R027 was excluded for missing data at week 8 and 12.
* Two-Sample Wilcoxon Rank Sums Test.
lamivudine 100 mg daily (n=46) in a blinded fashion. The 
baseline characteristics of the two treatment groups were shown 
in Table 1.
The number of withdrawal was 4 at week 48 for efficacy 
analysis (1 patient from clevudine group and 3 patients from 
lamivudine group) (Fig. 1). Hence, 88 patients (45 in the 
clevudine group and 43 in the lamivudine group) completed the 
48-week treatment period. One patient discontinued the study in 
the clevudine group due to withdrawal of consent and 3 patients 
discontinued the study in the lamivudine group due to withdrawal 
of consent, lamivudine resistance, and death.
2. Virologic and serologic endpoints 
Clevudine treatment for 48 weeks produced potent viral 
suppression compared to lamivudine treatment. At week 48, 33 
of 45 of patients (73%) in the clevudine group had undetectable 
serum HBV DNA levels by Amplicor PCR assay (less than 300 
copies/mL), while 17 of 43 of patients (40%) in the lamivudine 
group had undetectable serum HBV DNA levels (p=0.001) 
(Table 2). 
Median serum HBV DNA reductions from baseline at week 
48 were 4.27 and 3.17 log10 copies/mL in the clevudine and 
lamivudine groups, respectively (p<0.0001). At week 48, rate of 
HBeAg loss (18% in clevudine group versus 14% in lamivudine 
group) and HBeAg seroconversion (18% in clevudine group and 
12% in lamivudine group) was comparable in both groups. No 
viral breakthrough was observed in the clevudine group, while 
24% of patients in the lamivudine group showed viral 
breakthrough.
3. The Viral dynamic over the first 12 weeks 
A sub-study with the first 30 enrolled patients was performed. 
For each individual patient, the viral dynamics parameters (ε, μ, 
and a) were estimated by fitting the viral load function to the data 
using non-linear regression. 
Table 3 summarizes the estimated parameters by treatment 
groups. The p-values of the Wilcoxon Rank-Sum test were 0.060, 
0.371 and 0.672 for ε, μ and a, respectively. The differences of 
the median of the estimates between the groups were not 
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4. Biochemical endpoints
The proportion of patients who had normalization of serum 
ALT was 78% in the clevudine group and 81% in the lamivudine 
group at week 48 (p=0.591) (Table 2).
5. The Analysis of genotypic resistance 
Comparative analysis of genomic sequence of HBV isolated 
from the serum of the patients at baseline and at the time of viral 
rebound showed no resistance in the clevudine groups, while 11 
(24%) patients treated with lamivudine was found to have 
lamivudine-related resistance at the end of 48 weeks of treatment.
6. Safety and tolerability
The drug compliance was 99% during the study period. In the 
lamivudine group, there were two discontinuations of study 
due to adverse events (one with exacerbation of hepatitis B due 
to lamivudine resistance and another due to liver failure led by 
lamivudine resistance).
During the treatment period, the incidence of adverse events 
was similar in the two groups (clevudine group: 39%, lamivudine 
group: 33%). The most frequent adverse events (occurring in ≥
5% of patients), were flu-like symptoms (22%), headache and 
epigastric pain in the clevudine group. In the lamivudine group, 
the most frequent adverse events were flu-like symptoms (17%), 
increases in ALT and AST level. The incidence of serious 
adverse events (SAEs) during treatment was 7% (3/46) in the 
clevudine group and 9% (4/46) in the lamivudine group. From 
the 3 SAEs reported in the clevudine group, 2 SAEs were 
exacerbation of hepatitis B which resolved without any treatment 
and 1 SAE was myopathy reported at week 43 with grade 3 of 
creatinine phosphate kinase (CPK) value which was resolved 
after discontinuation of clevudine treatment. From the 4 SAEs 
reported in the lamivudine group, 1 SAE was hospitalization due 
to back pain and 3 SAEs were exacerbation of hepatitis B. One 
patient died in the lamivudine group due to liver failure led by 
lamivudine resistance. The incidence of ≥ grade 3 laboratory 
abnormality was similar in both groups except red blood cell, 
mean cell volume and CPK. The incidence of ≥ grade 3 
laboratory abnormality was 6.7% and 0% in the clevudine and 
lamivudine groups, respectively.
DISCUSSION
In this randomized double-blinded study, clevudine 30 mg 
daily was shown to be a highly potent antiviral activity in 
HBeAg-positive chronic hepatitis B patients compared to 
lamivudine. Clevudine suppressed HBV DNA by a median of 
4.27 log10 copies/mL, while the reduction serum HBV DNA was 
only 3.17 log10 copies/mL in the lamivudine group. The 
proportion of patients with negative HBV DNA (i.e. <300 
copies/ml) at week 48 which is the primary endpoint was 73% in 
the clevudine group and 40% in the lamivudine group which 
shows the statistically significant difference. 
Although direct head-to-head comparisons are not available, 
this degree of HBV DNA reduction by clevudine at week 48 
(73% with negative HBV DNA by Amplicor PCR) compared 
favorably to adefovir 10 mg daily (21%), entecavir 0.5 mg daily 
(67%) and telbivudine 600 mg daily (60%).
12-14
From previous study, we have learned that early viral 
suppression may predict long-term efficacy during antiviral 
therapy. Similar to an earlier studies,
7,8 clevudine is again shown 
to be superior to lamivudine in early viral suppression, with the 
proportion of patients with negative HBV DNA being 47% in the 
clevudine group and 22% in the lamivudine group at week 24. In 
addition, by measuring serum HBV DNA levels with a more 
sensitive assay, further analysis was performed to estimate viral 
clearance kinetics, in the sub-study.
10 However, the median of the 
estimates for viral dynamics between the groups were not 
statistically significant and this could be related to the small 
number of patients being studied. In our current study, the 
proportion of patients with normalization of serum ALT at week 
48 was similar in both groups, 78% and 81% in the clevudine and 
lamivudine groups, respectively. Also, the rate of HBeAg loss 
and HBeAg seroconversion were similar in the two groups. This 
is comparable to the previous 24 weeks clevudine study. 
Lamivudine has been one of the most widely used nucleoside 
analogues for CHB, largely due to its ability to significantly 
reduce HBV replication, favorable tolerability profile and 
relatively low cost. However, suppression of HBV DNA is not 
sustained in all patients and after only 6 months of continuous 
treatment, substitutions at position 204 in the tyrosine- 
methionine-aspartate-aspartate (YMDD) locus of HBV DNA 
polymerase can be detected. This YMDD mutation is the main 
cause of resistance to lamivudine, the incidence of which 
increases with treatment duration-approaching 70% after 4-5 
years of continuous drug exposure.
15 YMDD mutant HBV is 
associated with a diminished clinical and virologic responses that 
may lead to a significant number of patients experiencing 
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therapy in patients who develop YMDD mutations can be 
associated with ALT flares. Hence, it is of great importance to 
have other nucleoside analogues with lower rate of viral 
resistance. In our current study, by analyzing the genomic 
sequence of HBV isolated from the serum of the patients treated 
with clevudine showed no viral resistance, while 24% of patients 
in the lamivudine group showed lamivudine-related resistance 
(rtL180M, rtM204I/V). In the latter patients, there was associated 
viral rebound during 48-week treatment period. Further evaluation 
is necessary to understand the resistance rate with long-term 
treatment of clevudine.
The safety evaluation was performed for all patients who had 
taken at least one dose of study medication after randomization. 
Incidence of adverse event during the 48-week treatment period 
was similar between clevudine and lamivudine groups. During 
48-week treatment period, SAEs were reported from 3 patients in 
the clevudine group and 4 patients in the lamivudine group. 
From the 3 SAEs reported in the clevudine group, 2 SAEs were 
exacerbation of hepatitis B which were resolved without special 
treatment and 1 SAE was myopathy which was resolved after 
stopping of clevudine therapy. From the 4 SAEs reported in the 
lamivudine group, 1 SAE was hospitalization due to back pain 
and 3 SAEs were exacerbation of hepatitis. From them, one 
patient died due to liver failure led by lamivudine resistance. The 
incidence of ≥grade 3 lab abnormality was similar in both 
groups except red blood cell, mean cell volume and creatinine 
phosphate kinase parameters. 
Myopathy was reported during clevudine therapy of 8-13 
months.
16 During 48-week treatment period in this study, there 
was one SAE of myopathy reported at week 43 with grade 3 of 
CPK value in the clevudine group, which was resolved after 
discontinuation of clevudine treatment. 
In conclusion, 48-week dosing with clevudine 30 mg daily 
showed superior viral suppression to lamivudine 100 mg daily in 
HBeAg-positive chronic hepatitis B patients.
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